05 · Five talking points

Five talking points

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Five talking points across your briefs

  1. A second pan-RAS drug, Erasca’s ERAS-0015, reports responses in pancreatic cancer, from a small Phase 1 with no control group. Claim
  2. Daraxonrasib plus chemotherapy reached a 60.7% response rate first line in 61 patients; the randomized test is still to come. Claim
  3. Actinogen’s Xanamem missed its pivotal Alzheimer’s primary; the company now points to older patients. Claim
  4. An RNAi drug dosed four times a year is now approved for generalized myasthenia gravis, per Alnylam. Claim
  5. Sanofi’s reported interest in Insmed is a press report, not an announced deal. Analysis